Hyperliquid continues to draw major institutional interest as another Nasdaq-listed firm, Lion Group Holding Ltd (LGHL), announces a $600 million facility to launch a HYPE-focused treasury strategy. Lion Group Holding Ltd, listed on Nasdaq and offering a trading platform for…Hyperliquid continues to draw major institutional interest as another Nasdaq-listed firm, Lion Group Holding Ltd (LGHL), announces a $600 million facility to launch a HYPE-focused treasury strategy. Lion Group Holding Ltd, listed on Nasdaq and offering a trading platform for…

Lion Group Holding announces $600m facility for HYPE treasury strategy

2025/06/19 03:01
2 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Hyperliquid continues to draw major institutional interest as another Nasdaq-listed firm, Lion Group Holding Ltd (LGHL), announces a $600 million facility to launch a HYPE-focused treasury strategy.

Lion Group Holding Ltd, listed on Nasdaq and offering a trading platform for a suite of products that includes total return swaps, contract-for-difference and over-the-counter stock options, announced its move on June 18, 2025.

That’s just a day after Eyenovia, a U.S.-based ophthalmic technology firm, said it planned to deploy $50 million into a Hyperliquid (HYPE) treasury initiative. The news hasn’t catalyzed fresh gains for HYPE price, notably amid prevailing market conditions.

However, Eyenovia and LGHL highlight the growing institutional interest in the native token of Hyperliquid, a decentralized finance-focused blockchain and platform.

LGHL eyes Hyperliquid (HYPE) treasury with initial $600m 

According to Lion Group, the objective is clear: build the largest Hyperliquid treasury in the world. Eyenovia has expressed similar ambitions, hinting at a potential race to become the “Strategy of HYPE.”

Michael Saylor’s Strategy (formerly MicroStrategy) remains the top corporate holder of Bitcoin (BTC) on its balance sheet among publicly-listed companies. The U.S.-based firm has inspired a whole range of BTC treasury firms – with Ethereum, XRP and Solana now seeing similar trends.

Hyperliquid is the latest token to capture attention. LGHL is relaunching its crypto operations to align with its entry into the DeFi ecosystem, noting in a press release:

The company is relaunching its crypto operations amid the quest to tap into the decentralized finance ecosystem, LGHL noted in a press release.

The company is also considering secondary listings on the Tokyo Stock Exchange and Singapore Exchange, which would make it the first HYPE treasury firm publicly listed in Asia.

LGHL also eyes Solana, Sui treasury initiaives

According to Lion Group Holding CEO Wilson Wang, the launch of the HYPE treasury isn’t the company’s only plan. An on-chain vision also includes treasury reserves built with other layer-1 tokens.

That means plans for the strategic accumulation of Solana (SOL) and Sui (SUI). If this happens, the company will use BitGo to custody and stake its SOL and SUI.

SOL is the sixth largest cryptocurrency by market cap with over $76 billion. Meanwhile, HYPE and SUI are currently the 11th and 12th largest with $12.9 billion and $9.4 billion respectively.

Market Opportunity
Hyperliquid Logo
Hyperliquid Price(HYPE)
$30,71
$30,71$30,71
+2,77%
USD
Hyperliquid (HYPE) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09